News | Cardiovascular Ultrasound | June 13, 2016

Calculating Aortic Flow Rate Superior Test for Patient Risk Stratification

Mayo Clinic study finds echocardiography suitable test to evaluate heart function via dobutamine response

ASE 2016, Mayo Clinic study, echocardiography, aortic flow rate, patient risk stratification

June 13, 2016 — Researchers from Mayo Clinic believe they have found a better way to risk stratify some of their most fragile patients.

Patients with reduced left ventricular ejection fraction (LFLGAS) being evaluated with dobutamine, a medically induced “stressor,” to view their heart function at work need special care. Looking at a cohort of these patients, the researchers found that using echocardiography to measure their aortic flow rate was a good predictor for their risk. “Our work highlights, for the first time, the importance of calculating aortic valve flow rate to risk stratify patients undergoing dobutamine stress echo for a low-flow, low-gradient aortic stenosis. We showed that flow rate goes above and beyond contractile reserve, which is what is being used right now, to risk stratify these patients,” said Said Alsidawi, M.D.

Researchers on the study, Low-flow, Low-gradient Aortic Stenosis: Prognostic Value of Flow Rates vs. Stroke Volume During Dobutamine Echocardiography, included Alsidawi, Robert B. McCully, Christopher G. Scott, Sorin V. Pislaru, Patricia A. Pellikka, Mackram F. Eleid, Jae K. Oh, and Vuyisile T. Nkomo from the Division of Cardiovascular Diseases, Mayo Clinic School of Medicine, Rochester, Minn.

This finding could be useful for many clinicians as patients presenting with low ejection fractions (EF) could be exhibiting an early sign of heart failure. These clinicians need good diagnostic options to assess whether valve replacement surgery or other therapies are needed.

Alsidawi presented a poster based on this research during the American Society of Echocardiography 27th Annual Scientific Sessions, June 10-14 in Seattle. This research was submitted as part of the “Valvular Heart Disease” topic area.

For more information: www.asescientificsessions.org


Related Content

Feature | Cardiovascular Ultrasound | Kyle Hardner

The demand for ultrasound has outpaced the supply of trained sonographers over the past 15 years, straining hospital ...

Home March 11, 2026
Home
News | Cardiovascular Ultrasound

Septe. 30, 2025 -- GE HealthCare Vivid iq Ultrasound system has been selected by NASA for delivery to the International ...

Home October 09, 2025
Home
News | Cardiovascular Ultrasound

Sept. 26, 2025 — A new guideline from the American Society of Echocardiography (ASE) offers updated and expanded ...

Home October 03, 2025
Home
News | Cardiovascular Ultrasound

Aug. 27, 2025 — Royal Philips has released Transcend Plus, the next generation of its EPIQ CVx and Affiniti CVx ...

Home August 27, 2025
Home
News | Cardiovascular Ultrasound

Aug. 14, 2025 — Philips has announced a plan for new investments of more than $150 million in U.S. manufacturing and ...

Home August 14, 2025
Home
News | Cardiovascular Ultrasound

March 24, 2025 — FUJIFILM Healthcare Americas Corp. and Us2.ai have partnered to equip Fujifilm’s LISENDO 800 ...

Home March 24, 2025
Home
News | Cardiovascular Ultrasound

Feb. 11, 2025 — UltraSight, a company committed to enhancing the efficiency and productivity of cardiac ultrasound ...

Home February 18, 2025
Home
News | Cardiovascular Ultrasound

May 30, 2024 — A recent study published in the European Heart Journal highlights the significant enhancements that the ...

Home May 30, 2024
Home
News | Cardiovascular Ultrasound

April 5, 2024 — Cardiawave SA, a French medtech company that has developed an innovative Non-Invasive focused Ultrasound ...

Home April 05, 2024
Home
News | Cardiovascular Ultrasound

August 24, 2023 —Royal Philips, a global leader in health technology, highlighted how it integrates AI in cardiac ...

Home August 24, 2023
Home
Subscribe Now